<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12476">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481767</url>
  </required_header>
  <id_info>
    <org_study_id>106069</org_study_id>
    <nct_id>NCT00481767</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.</brief_title>
  <official_title>Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Senegal: Ministere de la sante</authority>
    <authority>Tanzania: TFDA (Tanzania Food and Drugs Authority)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the central cause
      of cervical cancer. The current study is designed to assess the immunogenicity and safety of
      GlaxoSmithKline Biologicals' HPV vaccine 580299 in female subjects aged 10-25 years enrolled
      in Africa.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
      2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies</measure>
    <time_frame>At Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was a subject with antibody titers below 8 or 7 Enzyme-linked Immunosorbent Assay Units per milliliter (EL.U/mL) for anti-HPV-16 and 18, respectively, before vaccination and antibody titers &gt;= 8 or 7 EL.U/mL for anti-HPV-16 and 18, respectively, after vaccination.
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as GMTs in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Month 2 and Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was a subject with antibody titers below 8 or 7 Enzyme-linked Immunosorbent Assay Units per milliliter (EL.U/mL) for anti-HPV-16 and 18, respectively, before vaccination and antibody titers &gt;= 8 or 7 EL.U/mL for anti-HPV-16 and 18, respectively, after vaccination.
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs for Anti-HPV-16 and Anti-HPV-18 Antibodies</measure>
    <time_frame>At Month 2 and Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as GMTs in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local and General Symptoms</measure>
    <time_frame>Within 7 days (Day 0-6) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms were pain and swelling at the injection site. Solicited general symptoms were arthralgia, fatigue, fever (defined as axillary temperature &gt;= 37.5 degrees Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 30 days (Day 0-29) after any vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any= any unsolicited AE regardless of intensity and relationship to vaccination.
Grade 3= an unsolicited AE that prevented normal everyday activity Related= unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)</measure>
    <time_frame>Up to Month 7 and from Month 7 up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Month 7 and up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancies and Their Outcomes</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pregnancy outcomes were ectopic pregnancy, elective termination no apparent congenital anomaly, live infant no apparent congenital anomaly, premature live infant no apparent congenital anomaly, lost to follow-up and spontaneous abortion no apparent congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Senegalese Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>At Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parameters assessed were:
Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC).
Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title.
For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>At Month 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Senegalese Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>At Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</measure>
    <time_frame>At Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">676</enrollment>
  <condition>HPV-16/18 Infections</condition>
  <condition>Cervical Neoplasia</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CervarixTM</intervention_name>
    <description>Three doses of vaccine/control will be administered according to a 0, 1, 6 month schedule</description>
    <arm_group_label>Cervarix Group</arm_group_label>
    <other_name>GlaxoSmithKline Biologicals' HPV vaccine 58029</other_name>
    <other_name>HPV-16/18 L1 AS04 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo vaccine (Al(OH)3)</intervention_name>
    <description>Three doses of vaccine/control will be administered according to a 0, 1, 6 month schedule</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parents/legally
             acceptable representative can and will comply with the requirements of the protocol
             should be enrolled in the study.

          -  A female between, and including, 10 and 25 years of age at the time of the first
             vaccination.

          -  Written or oral, signed or thumb printed or witnessed informed consent obtained from
             the subject prior to enrolment. For subjects below legal age of consent, written or
             oral, signed or thumb printed or witnessed informed consent obtained from the
             subject's parent or legally acceptable representative. In addition, a written or
             oral, signed or thumb printed and witnessed informed assent must be obtained from the
             subject.

          -  Free of obvious health problems as established by medical history, clinical
             examination and laboratory testing before entering into the study.

          -  Subjects must have a negative urine pregnancy test at the screening visit and at
             Visit 1 (Day 0).

          -  Subjects must be seronegative for human immunodeficiency virus (HIV) at the screening
             visit.

          -  Subjects must be of non-childbearing potential, or, if of childbearing potential, she
             must be abstinent or have used adequate contraceptive precautions for 30 days prior
             to vaccination, have a negative pregnancy test and must agree to continue such
             precautions for two months after completion of the vaccination series. Subjects who
             reach menarche during the study and therefore are of childbearing potential must
             agree to follow the same precautions.

          -  Subjects must have had no more than 6 sexual partners prior to enrolment.

          -  Subjects must be willing to undergo HIV voluntary counselling and testing and must be
             willing to be informed of their HIV status. Subjects below legal age of consent must
             also be willing to have their parent or legally acceptable representative informed of
             their HIV status.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days preceding the first dose of study vaccine, or planned
             use during the study period (up to Month 12).

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose or planned administration during the study
             period.

          -  Administration of a vaccine not foreseen by the study protocol within 30 days before
             the first dose of vaccine. Enrolment will be deferred until the subject is outside of
             specified window.

          -  Planned administration of a vaccine not foreseen by the study protocol within 30 days
             before and 30 days after any dose of study vaccine.

          -  Previous vaccination against HPV, or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  Previous administration of components of the investigational vaccine

          -  Cancer or autoimmune disease under treatment.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             HIV infection based on laboratory testing performed during the screening visit.

          -  Hypersensitivity to latex

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine/control.

          -  Acute disease at the time of enrolment.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory testing
             performed at the screening visit.

          -  History of any neurologic disorders or seizures.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Pregnant or breastfeeding female.

          -  A women planning to become pregnant, likely to become pregnant or planning to
             discontinue contraceptive precautions during the study period, up to two months after
             the last vaccine dose.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
    <country>Tanzania</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>April 7, 2011</lastchanged_date>
  <firstreceived_date>May 31, 2007</firstreceived_date>
  <firstreceived_results_date>February 24, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Cervical cancer;</keyword>
  <keyword>Human papillomavirus (HPV) vaccine</keyword>
  <keyword>HPV;</keyword>
  <keyword>Papillomavirus;</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="450"/>
                <participants group_id="P2" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="418"/>
                <participants group_id="P2" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="450"/>
                <measurement group_id="B2" value="226"/>
                <measurement group_id="B3" value="676"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16.9" spread="4.36"/>
                <measurement group_id="B2" value="16.8" spread="4.16"/>
                <measurement group_id="B3" value="16.9" spread="4.29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="450"/>
                <measurement group_id="B2" value="226"/>
                <measurement group_id="B3" value="676"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies</title>
        <description>A seroconverted subject was a subject with antibody titers below 8 or 7 Enzyme-linked Immunosorbent Assay Units per milliliter (EL.U/mL) for anti-HPV-16 and 18, respectively, before vaccination and antibody titers &gt;= 8 or 7 EL.U/mL for anti-HPV-16 and 18, respectively, after vaccination.
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
        <time_frame>At Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies</title>
            <description>A seroconverted subject was a subject with antibody titers below 8 or 7 Enzyme-linked Immunosorbent Assay Units per milliliter (EL.U/mL) for anti-HPV-16 and 18, respectively, before vaccination and antibody titers &gt;= 8 or 7 EL.U/mL for anti-HPV-16 and 18, respectively, after vaccination.
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>10-14 years anti-HPV-16 (N=130;59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-16 (N=190;97)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-18 (N=128; 56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-18 (N=212;98)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Titers were expressed as GMTs in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
        <time_frame>At Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="114"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) of Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Titers were expressed as GMTs in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>10-14 years anti-HPV-16 (N=142;65)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18591.3" lower_limit="16433.0" upper_limit="21033.1"/>
                  <measurement group_id="O2" value="4.8" lower_limit="4.2" upper_limit="5.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-16 (N=237;112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10664.0" lower_limit="9668.5" upper_limit="11762.0"/>
                  <measurement group_id="O2" value="5.3" lower_limit="4.6" upper_limit="6.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-18 (N=141;66)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6409.8" lower_limit="5563.4" upper_limit="7385.0"/>
                  <measurement group_id="O2" value="3.9" lower_limit="3.6" upper_limit="4.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-18 (N=235;114)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3653.6" lower_limit="3343.9" upper_limit="3991.9"/>
                  <measurement group_id="O2" value="4.6" lower_limit="4.0" upper_limit="5.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>A seroconverted subject was a subject with antibody titers below 8 or 7 Enzyme-linked Immunosorbent Assay Units per milliliter (EL.U/mL) for anti-HPV-16 and 18, respectively, before vaccination and antibody titers &gt;= 8 or 7 EL.U/mL for anti-HPV-16 and 18, respectively, after vaccination.
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
        <time_frame>At Month 2 and Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>A seroconverted subject was a subject with antibody titers below 8 or 7 Enzyme-linked Immunosorbent Assay Units per milliliter (EL.U/mL) for anti-HPV-16 and 18, respectively, before vaccination and antibody titers &gt;= 8 or 7 EL.U/mL for anti-HPV-16 and 18, respectively, after vaccination.
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>10-14 years anti-HPV-16 Month 2 (N=130;59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-16 Month 2 (N=190;96)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="190"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-16 Month 12 (N=128;59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-16 Month 12 (N=184;94)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-18 Month 2 (N=128;55)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-18 Month 2 (N=212;98)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-18 Month 12 (N=126;56)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-18 Month 12 (N=205;96)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="205"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
        <description>Titers were expressed as GMTs in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
        <time_frame>At Month 2 and Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="112"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>GMTs for Anti-HPV-16 and Anti-HPV-18 Antibodies</title>
            <description>Titers were expressed as GMTs in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
The groups were stratified by age for the analysis. The age strata were 10-14 years and 15-25 years.</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>10-14 years anti-HPV-16 Month 2 (N=142;64)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5340.2" lower_limit="4823.7" upper_limit="5912.0"/>
                  <measurement group_id="O2" value="4.5" lower_limit="4.0" upper_limit="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-16 Month 2 (N=237;112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3732.6" lower_limit="3436.6" upper_limit="4054.1"/>
                  <measurement group_id="O2" value="4.9" lower_limit="4.3" upper_limit="5.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-16 Month 12 (N=139;65)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4016.2" lower_limit="3323.3" upper_limit="4853.7"/>
                  <measurement group_id="O2" value="4.7" lower_limit="4.2" upper_limit="5.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-16 Month 12 (N=229;109)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2464.2" lower_limit="2196.5" upper_limit="2764.5"/>
                  <measurement group_id="O2" value="5.6" lower_limit="4.7" upper_limit="6.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-18 Month 2 (N=141;65)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3016.7" lower_limit="2677.4" upper_limit="3398.9"/>
                  <measurement group_id="O2" value="3.9" lower_limit="3.6" upper_limit="4.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-18 Month 2 (N=235;112)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2039.3" lower_limit="1861.3" upper_limit="2234.4"/>
                  <measurement group_id="O2" value="4.6" lower_limit="4.0" upper_limit="5.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>10-14 years anti-HPV-18 Month 12 (N=138;66)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1422.1" lower_limit="1170.0" upper_limit="1728.4"/>
                  <measurement group_id="O2" value="3.7" lower_limit="3.5" upper_limit="3.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>15-25 years anti-HPV-18 Month 12 (N=227;111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="855.9" lower_limit="768.3" upper_limit="953.5"/>
                  <measurement group_id="O2" value="4.6" lower_limit="4.0" upper_limit="5.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms were pain and swelling at the injection site. Solicited general symptoms were arthralgia, fatigue, fever (defined as axillary temperature &gt;= 37.5 degrees Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
        <time_frame>Within 7 days (Day 0-6) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="450"/>
                  <measurement group_id="O2" value="226"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Solicited Local and General Symptoms</title>
            <description>Solicited local symptoms were pain and swelling at the injection site. Solicited general symptoms were arthralgia, fatigue, fever (defined as axillary temperature &gt;= 37.5 degrees Celsius), gastrointestinal symptoms, headache, myalgia, rash and urticaria.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="166"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="111"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="118"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="189"/>
                  <measurement group_id="O2" value="109"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urticaria</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any= any unsolicited AE regardless of intensity and relationship to vaccination.
Grade 3= an unsolicited AE that prevented normal everyday activity Related= unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 30 days (Day 0-29) after any vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="450"/>
                  <measurement group_id="O2" value="226"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any= any unsolicited AE regardless of intensity and relationship to vaccination.
Grade 3= an unsolicited AE that prevented normal everyday activity Related= unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="235"/>
                  <measurement group_id="O2" value="142"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)</title>
        <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury</description>
        <time_frame>Up to Month 7 and from Month 7 up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="450"/>
                  <measurement group_id="O2" value="226"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With New Onset of Chronic Diseases (NOCDs) and Medically Significant Conditions (MSCs)</title>
            <description>NOCDs include autoimmune disorders, asthma, type I diabetes, allergies. MSC include AEs prompting emergency room or physician visits that are not related to common diseases or routine visits for physical examination or vaccination, or serious adverse events (SAEs) that are not related to common diseases. Common diseases include upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>NOCD Month 7 (N=450;226)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NOCD Month 7-12 (N=421;208)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MSC Month 7 (N=450;226)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="289"/>
                  <measurement group_id="O2" value="161"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MSC Month 7-12 (N=421;208)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="121"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>Up to Month 7 and up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="450"/>
                  <measurement group_id="O2" value="226"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>up to Month 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>up to Month 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancies and Their Outcomes</title>
        <description>Pregnancy outcomes were ectopic pregnancy, elective termination no apparent congenital anomaly, live infant no apparent congenital anomaly, premature live infant no apparent congenital anomaly, lost to follow-up and spontaneous abortion no apparent congenital anomaly.</description>
        <time_frame>Up to Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort on pregnant subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Pregnancies and Their Outcomes</title>
            <description>Pregnancy outcomes were ectopic pregnancy, elective termination no apparent congenital anomaly, live infant no apparent congenital anomaly, premature live infant no apparent congenital anomaly, lost to follow-up and spontaneous abortion no apparent congenital anomaly.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ectopic pregnancy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Elective termination</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Live infant</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Premature live infant</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lost to follow-up</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spontaneous abortion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Senegalese Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Parameters assessed were:
Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC).
Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title.
For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
        <time_frame>At Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort on Senegalese subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="198"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Senegalese Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
            <description>Parameters assessed were:
Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC).
Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title.
For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=8;4), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc.ABOVE (N=8;4), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=8;4), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=39;17), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=39;17), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=39;17), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=170;84), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=170;84), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=170;84), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=217;105), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="216"/>
                  <measurement group_id="O2" value="105"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=217;105), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=217;105), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. ABOVE (N=2;1), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. ABOVE (N=2;1), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. ABOVE (N=2;1), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=56;30), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=56;30), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=56;30), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=159;74), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=159;74), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=159;74), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=43;28), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=43;28), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=43;28), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. BELOW (N=19;10), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. BELOW (N=19;10), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. BELOW (N=19;10), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=155;67), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=155;67), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=155;67), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=75;33), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=75;33), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=75;33), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=142;72), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=142;72), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=142;72), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=77;41), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=77;41), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=77;41), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. BELOW (N=41;19), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. BELOW (N=41;19), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. BELOW (N=41;19), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=99;45), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=99;45), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=99;45), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=48;35), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=48;35), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=48;35), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=169;70), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=169;70), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=169;70), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. ABOVE (N=8;3), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. ABOVE (N=8;3), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. ABOVE (N=8;3), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=176;91), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=176;91), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="165"/>
                  <measurement group_id="O2" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=176;91), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=33;11), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=33;11), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=33;11), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=17;6), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=17;6), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=17;6), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA. pre-vacc. BELOW (N=2;3), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA. pre-vacc. BELOW (N=2;3), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA. pre-vacc. BELOW (N=2;3), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=198;96), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="194"/>
                  <measurement group_id="O2" value="96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=198;96), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=198;96), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=29;11), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=29;11), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=29;11), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=188;94), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176"/>
                  <measurement group_id="O2" value="89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=188;94), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=188;94), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=9;7), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=9;7), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=9;7), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=21;12), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=21;12), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=21;12), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=187;86), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=187;86), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=187;86), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
        <time_frame>At Month 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort on Tanzanian subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="187"/>
                  <measurement group_id="O2" value="96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
            <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=3;3), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=3;3), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=3;3), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=13;11), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=13;11), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=13;11), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=183;85), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=183;85), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=183;85), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. ABOVE (N=21;12), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. ABOVE (N=21;12), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. ABOVE (N=21;12), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=178;87), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="163"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=178;87), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=178;87), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=43;14), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=43;14), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=43;14), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=156;85), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=156;85), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="116"/>
                  <measurement group_id="O2" value="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=156;85), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=76;39), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=76;39), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=76;39), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=76;39), Month 7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=123;60), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=123;60), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=123;60), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. ABOVE (N=1;0), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. ABOVE (N=1;0), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. ABOVE (N=1;0), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=60;35), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=60;35), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=60;35), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=138;64), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="118"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=138;64), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=138;64), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=20;8), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=20;8), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=20;8), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=179;91), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=179;91), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=179;91), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=12;7), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=12;7), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=12;7), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=187;92), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=187;92), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=187;92), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;16), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;16), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;16), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;16), Month 7 MISSING</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=163;83), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=163;83), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=163;83), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=10;3), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=10;3), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=10;3), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. BELOW (N=5;0), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. BELOW (N=5;0), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. BELOW (N=5;0), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=184;96), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="180"/>
                  <measurement group_id="O2" value="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=184;96), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=184;96), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. ABOVE (N=11;7), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. ABOVE (N=11;7), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. ABOVE (N=11;7), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=2;1), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=2;1), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=2;1), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=186;91), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=186;91), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=186;91), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=17;7), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=17;7), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=17;7), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=0;2), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=0;2), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=0;2), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=182;90), Month 7 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="177"/>
                  <measurement group_id="O2" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=182;90), Month 7 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=182;90), Month 7 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Senegalese Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
        <time_frame>At Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort on Senegalese subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="211"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Senegalese Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
            <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=8;4), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc.ABOVE (N=8;4), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=8;4), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=38;17), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=38;17), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=38;17), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=165;81), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="139"/>
                  <measurement group_id="O2" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=165;81), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=165;81), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=211;102), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="210"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=211;102), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=211;102), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. ABOVE (N=2;1), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. ABOVE (N=2;1), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. ABOVE (N=2;1), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=56;29), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=56;29), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=56;29), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=153;72), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=153;72), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=153;72), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=43;28), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=43;28), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=43;28), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. BELOW (N=19;10), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. BELOW (N=19;10), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. BELOW (N=19;10), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=149;64), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=149;64), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=149;64), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=71;33), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=71;33), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=71;33), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=140;69), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=140;69), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=140;69), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=75;41), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=75;41), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=75;41), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. BELOW (N=38;19), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. BELOW (N=38;19), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. BELOW (N=38;19), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=98;42), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=98;42), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=98;42), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=45;34), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=45;34), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=45;34), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=166;68), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=166;68), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=166;68), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. ABOVE (N=8;3), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. ABOVE (N=8;3), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. ABOVE (N=8;3), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=173;88), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=173;88), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=173;88), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=30;11), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=30;11), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=30;11), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=17;6), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=17;6), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=17;6), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA. pre-vacc. BELOW (N=2;3), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA. pre-vacc. BELOW (N=2;3), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA. pre-vacc. BELOW (N=2;3), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=192;93), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="188"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=198;93), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=198;93), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=27;11), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=27;11), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=27;11), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=184;91), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="169"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=184;91), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=184;91), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=8;7), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=8;7), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=8;7), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=19;12), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=19;12), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=19;12), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=184;83), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=184;83), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=184;83), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
        <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
        <time_frame>At Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort on Tanzanian subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="194"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Tanzanian Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters Assessed</title>
            <description>Parameters assessed were: Alanine amino-transferase (ALT), basophils (BAS), creatinine (CREA), eosinophils (EOS), hematocrit (HC), lymphocytes (LYM), monocytes (MON), neutrophils (NEU), platelets (PLA), red blood cells (RBC), white blood cells (WBC). Number of subjects were separated with respect to their results at pre-vaccination, i.e. whether their results were in, above or below the normal range. N for each category at pre-vaccination noted in category title. For each parameter and for each range it was assessed whether the values of the subjects were in, above or below the normal range.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=3;4), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=3;4), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. ABOVE (N=3;4), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=13;11), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=13;11), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. BELOW (N=13;11), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=190;87), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                  <measurement group_id="O2" value="73"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=190;87), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ALT, pre-vacc. NORMAL (N=190;87), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. ABOVE (N=23;13), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. ABOVE (N=23;13), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. ABOVE (N=23;13), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=183;89), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="174"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=183;89), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BAS, pre-vacc. NORMAL (N=183;89), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=42;14), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=42;14), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. BELOW (N=42;14), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=164;88), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=164;88), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="116"/>
                  <measurement group_id="O2" value="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>CREA, pre-vacc. NORMAL (N=164;88), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=79;43), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=79;43), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. ABOVE (N=79;43), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=127;59), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=127;59), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>EOS, pre-vacc. NORMAL (N=127;59), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=63;38), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=63;38), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. BELOW (N=63;38), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=143;64), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=143;64), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HC, pre-vacc. NORMAL (N=143;64), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=18;8), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=18;8), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. ABOVE (N=18;8), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=188;94), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="168"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=188;94), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LYM, pre-vacc. NORMAL (N=188;94), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=12;7), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=12;7), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. ABOVE (N=12;7), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=194;95), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="184"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=194;95), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MON, pre-vacc. NORMAL (N=194;95), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;17), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;17), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. BELOW (N=36;17), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=170;85), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                  <measurement group_id="O2" value="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=170;85), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NEU, pre-vacc. NORMAL (N=170;85), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=10;2), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=10;2), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. ABOVE (N=10;2), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. BELOW (N=5;0), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. BELOW (N=5;0), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. BELOW (N=5;0), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=191;100), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="185"/>
                  <measurement group_id="O2" value="96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=191;100), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>PLA, pre-vacc. NORMAL (N=191;100), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. ABOVE (N=10;7), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. ABOVE (N=10;7), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. ABOVE (N=10;7), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=3;2), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=3;2), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. BELOW (N=3;2), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=193;93), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="182"/>
                  <measurement group_id="O2" value="91"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=193;93), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>RBC, pre-vacc. NORMAL (N=193;93), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=17;6), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=17;6), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. ABOVE (N=17;6), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=0;2), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=0;2), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. BELOW (N=0;2), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=189;94), Month 12 NORMAL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="165"/>
                  <measurement group_id="O2" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=189;94), Month 12 BELOW</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>WBC, pre-vacc. NORMAL (N=189;94), Month 12 ABOVE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Female subjects received 3 doses of Cervarix at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Female subjects received 3 doses of placebo at Month 0, 1 and 6 intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pyomyositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy vitamin b6 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="375" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="375" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="166" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Malaria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
